Skip to main content

Advertisement

SpringerLink
Log in

Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Introduction

The objective of this study was to quantitatively evaluate the effects of daily teriparatide on rheumatoid arthritis patients using predicted bone strength (PBS) assessed by quantitative computed tomography-based finite-element analysis (QCT/FEA) and using bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DXA), and to prospectively investigate clinical determinants associated with PBS and BMD increases.

Materials and Methods

Participants comprised 39 patients (mean age, 69 years; disease activity score assessing 28 joints with CRP, 3.0; previous vertebral fractures, 82%) enrolled in this study. BMD by DXA and PBS by QCT/FEA of lumbar spine (LS) and proximal femur were measured at baseline, and after 6 and 12 months. In the groups showing increases in these values, variables that may have affected these increases were evaluated using univariate logistic regression analysis.

Results

Daily teriparatide treatment significantly increased not only LS BMD, but also LS PBS in RA patients with osteoporosis after both 6 and 12 months of treatment. Increases in N-terminal type I procollagen propeptide (PINP) at 1 and 3 months were significantly associated with increased LS PBS at 12 months according to univariate logistic regression analysis. The threshold value for increased PINP at 1 month for increased PBS at 12 months was 75 µg/L.

Conclusions

Increased LS PBS at 12 months was predicted by increased PINP at 1 month from baseline.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hoes JN, Bultink EI, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16:559–571

    Article  CAS  Google Scholar 

  2. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112

    Article  Google Scholar 

  3. Omata Y, Hagiwara F, Nishino J, Matsudaira K, Kadono Y et al (2014) Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients. J Bone Miner Metab 32:725–731

    Article  Google Scholar 

  4. Ochi K, Inoue E, Furuya T, Ikari K, Toyama Y et al (2015) Ten-year incidence of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int 26:961–968

    Article  CAS  Google Scholar 

  5. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. J Engl J Med 344:1434–1441

    Article  CAS  Google Scholar 

  6. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trail. Arthritis Rheum 60:3346–3355

    Article  CAS  Google Scholar 

  7. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916

    Article  CAS  Google Scholar 

  8. Jiang Y, Zhao JJ, Mitlak BH, Wanq O, Genant HK et al (2003) Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941

    Article  CAS  Google Scholar 

  9. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502

    Article  CAS  Google Scholar 

  10. Soen S, Fujiwara S, Takayanagi R, Kajimoto K, Tsujimoto M et al (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan fracture Observational Study (JFOS). Curr Med Res Opin 33:2049–2056

    Article  CAS  Google Scholar 

  11. Link TM, Kazakia G (2020) Update on imaging-based measurement of bone mineral density and quality. Curr Rheumatol Rep 22:13. https://doi.org/10.1007/s11926-020-00892-w

    Article  CAS  PubMed  Google Scholar 

  12. Solomon DH, Kremer J, Cutis JR, Hochberq MC, Reed G et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925

    Article  Google Scholar 

  13. NIH consensus development panel on osteoporosis prevention (2001) Diagnosis and therapy. Osteoporosis prevention diagnosis and therapy. JAMA 285:785–796

    Article  Google Scholar 

  14. Dall’Ara E, Pahr D, Varga P, Kainberger F, Zysset P (2012) QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int 23:563–572

    Article  Google Scholar 

  15. Imai K, Ohnishi I, Bessho M, Nakamura K (2006) Nonlinear finite element model predicts vertebral bone strength and fracture site. Spine 31:1789–1794

    Article  Google Scholar 

  16. Bessho M, Ohnishi I, Matsuyama J, Matsumoto T, Imai K et al (2007) Prediction of strength and strain of the proximal femur by a CT-based finite element method. J Biomech 40:1745–1753

    Article  Google Scholar 

  17. Kaneko M, Ohnishi I, Matsumoto T, Ohashi S, Bessho M et al (2016) Prediction of proximal femur strength by a quantitative computed tomography-based finite element method- Creation of predicted strength data of the proximal femur according to age range in a normal population. Modern Rheumatol 26:151–155

    Article  Google Scholar 

  18. Imai K, Ohnishi T, Matsumoto T, Yamamoto S, Nakamura K (2009) Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 20:801–810

    Article  CAS  Google Scholar 

  19. Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y et al (2008) Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum 58:3340–3349

    Article  CAS  Google Scholar 

  20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  CAS  Google Scholar 

  21. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798–803

    Article  CAS  Google Scholar 

  22. Gallagher JC, Rosen CJ, Chen P, Marcus R (2006) Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 39:1268–1275

    Article  CAS  Google Scholar 

  23. Gluer CC (1999) Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14:1952–1962

    Article  CAS  Google Scholar 

  24. Hair JF, Anderson RE, Tatham RL, Black WC (1998) Multivariate data analysis with readings, 5th edn. Prentice-Hall, Englewood Cliffs

    Google Scholar 

  25. Hosmer DW, Lemeshow S (2000) Assessing the fit of the model. In: Hosmer DW, Lemshow S (eds) Applied logistic regression, 2nd edn. Wiley, New York, pp 143–202

    Chapter  Google Scholar 

  26. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH et al (2012) Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 50:165–170

    Article  CAS  Google Scholar 

  27. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrenrons J, Boonen S et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600

    Article  CAS  Google Scholar 

  28. Ebina K, Hashimoto J, Shi K, Kashii M, Hisao M et al (2014) Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int 25:2755–5765

    Article  CAS  Google Scholar 

  29. Ono K, Ohashi S, Oka H, Kadono Y, Yasui T et al (2016) The impact of joint disease on the Modified Health Assessment Questionnaire scores in rheumatoid arthritis patients: a cross-sectional study using the national database of rheumatic diseases by iR-net in Japan. Mod Rheumatol 26:529–533

    Article  Google Scholar 

  30. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056–5062

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Joint Surgery, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan

    Kumiko Ono

  2. Department of Orthopaedic Surgery, Sagamihara Hospital, National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagamihara-shi, Sagamihara, Kanagawa, 252-0315, Japan

    Satoru Ohashi

  3. Department of Medical Research and Management for Musculoskeletal Pain, Faculty of Medicine, 22nd Century Medical and Research Center, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan

    Hiroyuki Oka

  4. Department of Orthopaedic Surgery, Saitama Medical University Hospital, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama, 350-0495, Japan

    Yuho Kadono

  5. Department of Orthopaedic Surgery, Teikyo University Mizonokuchi Hospital, 5-1-1 Futago, Takatsu-ku, Kawasaki-shi, Kawasaki, Kanagawa, 213-8507, Japan

    Tetsuro Yasui

  6. Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan

    Takumi Matsumoto, Yasunori Omata & Sakae Tanaka

Authors
  1. Kumiko Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyuki Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuho Kadono
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuro Yasui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takumi Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasunori Omata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sakae Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation and data collection were performed by KO, YK, TY, TM and YO. SO and HO contributed to analysis and interpretation of data. The first draft of the manuscript was written by KO and reviewed and edited by SO and ST. All authors commented on previous versions of the manuscript. Final manuscript was supervised by ST, and all authors read and approved the final manuscript.

Corresponding author

Correspondence to Satoru Ohashi.

Ethics declarations

Conflict of interest

All authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ono, K., Ohashi, S., Oka, H. et al. Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients. J Bone Miner Metab 39, 270–277 (2021). https://doi.org/10.1007/s00774-020-01146-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-020-01146-6

Keywords

Search

Navigation